A simplified, rapid, selective HPLC method for determining five cytochrome P450 (CYP) probe drugs in single run is described. The five specific probe substrates of caffeine, chlorzoxazone, tolbutamide, metoprolol and midazolam, together with the internal standard diazepam, were extracted using liquid-liquid extraction in rat plasma, followed by high-performance liquid chromatography (HPLC) using a C 18 column (5 m mm particle size, 250؋ ؋4.6 mm i.d.). The mobile phase consisted of a methanol and 50 mM phosphate buffer (pH 3.4, 65 : 35). All analytes were separated simultaneously in a single run that lasted less than 22 min. The detection limits range from 0.2-50 m mg/ml for caffeine, 0.5-50 m mg/ml for tolbutamide, metoprolol and midazolam, 0.2-100 m mg/ml for chlorzoxazone, respectively. The intra-and inter-day precisions for five probe substrates were 1.38-11.10% and 3.39-11.33%, respectively, and the accuracy of five probe substrates ranged from 94.92-113.06% and 92.18-112.62%. The limit of quantification (LOQ) was 0.5 m mg/ml for tolbutamide, midazolam and metoprolol, 0.2 m mg/ml for caffeine and chlorzoxazone. The present method provides a robust, fast analytical tool for the five-probe drug cocktail. Finally, the method was suitable for determining the plasma concentration of these compounds and evaluating the CYP1A2, 2C9, 2D6, 2E1 and 3A4 activities in rats.
Variability in drug response can be attributed in part to variability in the activity of drug-metabolizing enzymes. One of the most important drug metabolizing enzyme systems in mammal is the cytochrome P450 (CYP) enzyme family, which is responsible for the oxidative metabolism of numerous endogenous compounds and xenobiotics. Among the various CYP isozymes, CYP1A2, 2C9, 2D6, 2E1 and 3A4 are the major isoforms responsible for the metabolism of most of commercial drugs. 1) Probe drugs have been widely used for phenotyping various individual CYP activities, and this approach has been widely used in many investigations in the field of drug metabolism and pharmacogenetics. Probe drugs have been used alone and in combinations, offering necessary benefits. Administration of multiple compounds simultaneously as a "cocktail" strategy, providing no metabolic or analytical interactions from each other, is useful to enhance drug efficiency. [2] [3] [4] Several cocktail combinations have been described including the 'Pittsburgh cocktail', 5) 'GW cocktail', 6) 'Cooperstown cocktail', 7) 'Karolinska cocktail', 8) ' Blakey cocktail', 9) 'Sharma cocktail', 10) 'Jerdi cocktail', 11) 'Krosser cocktail', 12) and others. 13) These methods can minimize intra-subject variability over time. So far most of the analytical methods for these cocktail are tedious and usually require a separate highperformance liquid chromatography (HPLC), gas chromatography (GC) or pricey and rigorous liquid chromatography/ mass spectrometry (LC/MS) technique for each probe drug, not for all probe drugs in a single run.
To overcome the above-mentioned inconvenience, we have recently developed a novel 5 probe-drug cocktail, consisting of caffeine, chlorzoxazone, tolbutamide, metoprolol and midazolam. The aim of this study was to establish and optimize a simplified, rapid, selective HPLC method to determine 5 probe-drug in a single run with UV detector for the evaluation of CYP1A2, 2C9, 2D6, 2E1 and 3A4 isozyme activity, respectively. This method was evaluated in terms of recovery, linearity, precision and accuracy, and applied to the analyse of plasma samples in rat. HPLC-grade methanol was supplied by the Jiangsu Huaiyin Institute of Fine Chemicals (Jiangsu, China). All other reagents were of analytical grade from Concord Technology (Tianjin, China) Co., Ltd. Antigen free plasma was obtained from breeding male rats weighing 180-220 g purchased from the Tianjin Medicine Research Institute (Tianjin, China).
MATERIALS AND METHODS

Chemicals and Reagents
Instrumentation LC data was generated in an Agilent 1100 Series LC system (Agilent, Palo Alto, U.S.A.) constituted of a quaternary pump, a vacuum degaser, an autosampler, a thermostated column compartment, a diode-array and UV detectors. An Agilent Chemstation software package was used for instrument control, data acquisition and data handling. LC analyses were carried out on C 18 column (250 mmϫ4.6 mm i.d., particle size 5 mm).The flow rate was set at 1 ml/min. Unless otherwise indicated, the mobile phase consisted of a mixture of methanol and 50 mM phosphate buffer (pH 3.4, 65 : 35). UV detection was 230 nm.
Standard and Sample Preparation. 1. Standard Solutions The primary stock solutions of the studied drugs were prepared at 1 mg/ml in methanol, except for midazolam dissolved in water. The stock solution of IS, diazepam, was prepared at 1 mg/ml in methanol. The working solution of each analyte was prepared in water from stock solutions.
Plasma Standard and Quality Control Samples
Standard calibration samples were prepared by spiking the blank rat plasma with the working solution of each analyte. The plasma concentrations for caffeine were 0.2, 0.5, 1, 2, 5, 10, 20 and 50 mg/ml, 0.2, 0.5, 1, 2, 5, 10, 20, 50 and 100 mg/ml for chlorzoxazone, metoprolol and midazolam, 0.5, 1, 2, 5, 10, 20, 50 mg/ml for tolbutamide.
Quality control (QC) samples were prepared in a similar manner at their different concentrations, i.e. at the low, medium and high concentrations of 1, 10 and 50 mg/ml.
3. Sample Preparation Plasma sample (0.2 ml) containing five probe drugs was extracted with 2 ml chloroform after the addition of 20 ml of internal standard (diazepam, 200 mg/ml) in a polyethylene (PE) tube. After mixing for 2 min and centrifuging at 3500 rpm for 10 min, the organic phase 1.8 ml was removed and evaporated under a gentle stream of nitrogen at 40°C. The residue obtained was dissolved in 180 ml of the initial mobile phase and 40 ml was injected onto the HPLC system.
Liquid Chromatography An Agilent 1100 system, equipped with an autosampler was used. Chromatography was performed on a C 18 column (250 mmϫ4.6 mm, 5 mm). The mobile phase consisted of a methanol and 50 mM phosphate buffer (pH 3.4, 65 : 35). The flow-rate was 1 ml/min. UV detection was 230 nm. The total run time is 22 min per sample.
Method Validation Validation of the assay was conducted according to SFDA guidelines, with respect to the linearity, specificity, sensitivity, extraction recovery, precision and accuracy. Three QC samples at low, medium and high concentration levels were utilized for these tests, using the assay procedure described in the previous section.
1. Linearity and Sensitivity Calibration standards were prepared and analyzed in triplicate in three independent runs. Calibration curves were constructed using the analyte/IS peak area ratio versus the analyte concentration, and were fitted by linear least-squares regression analysis without weighting. To assess linearity, deviations of the mean calculated concentrations over three runs were set at Ϯ15% of nominal concentration, except for the lower limit of quantification where a deviation of Ϯ20% was permitted. The limit of quantification (LOQ) was determined based on the criteria that the analyte response at LOQ is 10 times the baseline noise, and the analyte response at LOQ can be determined with precision of ϫ20% and accuracy of 80-120%.
2. Recovery The extraction recoveries for the plasma samples were determined by the following procedure: (1) blank plasma was extracted with 2 ml chloroform after the addition of 20 ml of internal standard (diazepam, 200 mg/ml) in a PE tube and evaporated to dryness; the dry extract was then dissolved in an analyte standard solution, the final result thus representing 100% recovery. (2) QC samples spiked with the analyte were processed in a similar manner; their responses were determined and the compared to those from the blank samples spiked post-extraction, from step (1) above. For each analyte, the recovery experiment was performed with three QC concentrations (low, medium and high), with five plicate determinations at each concentration.
3. Precison and Accuracy QC samples in five replicates were analyzed on the same day to determine the intraday precision and accuracy, and on each of three separate days to determine inter-day precision and accuracy. Precision was calculated as the relative standard deviation (RSD), whereas accuracy was assessed as the percentage bias from the nominal concentration (% bias). The acceptable intraand inter-day precision and bias were set at Յ15%, except at the LOQ where they were set at Յ20%. Accuracy was expressed as percent recovery after analyzing drug-spiked plasma and comparing to the added amount.
RESULTS AND DISCUSSION
Optimization of Chromatographic Conditions
An important general limitation in the use of multiple probe drug cocktail for the evaluation of CYP isozyme activities is the complicated and tedious assay methodology of a cocktail. Thus, simultaneous determination of all the probe drugs using a simple, rapid, selective analytical method in a single run is most desirable. In our first investigations, a mobile phase consisting of acetonitrile and 50 mM phosphate buffer pH 3.7 was selected. Under these conditions, caffeine eluted in the injection peak, therefore acetonitrile was replaced by methanol. And the organic solvent percentage was varied between 20 and 80%. With 65% methanol during four minutes, caffeine was eluted without any interference, and subsequently a good separation of the other substances was obtained. Furthermore, we demonstrated that the tolbutamide peak tailed significantly at pH 4.0, and metoprolol and midazolam peak tailed significantly under pH 3.4, thus pH 3.4 was chosen for a complete separation of the drugs in less than 22 min, in order to reduce the analysis time and improve the peak symmetry. No interference was observed between endogenous compounds and the drugs under these elution conditions (Fig. 1) . In this study we used a liquid-liquid extraction procedure that enables to extract simultaneously all 6 analytes (including IS) from plasma, followed by chromatography with UV detection. These results show that our method is capable of generating the analytical data in a single run.
Method Evaluation Detector response linearity was performed by preparing at least seven triplicate calibration samples covering the range of expected concentrations. Calibration curves were obtained from spiked plasma samples as described previously. They were linear with equation YϭaXϩb for probe drugs. The linearity of the calibration graph was demonstrated by excellent coefficient (Table 1) .
LOQ was 0.5 mg/ml for tolbutamide, midazolam and metoprolol 0.2 mg/ml for caffeine and chlorzoxazone. The low concentration of QC sample was fixed at 1 mg/ml according to the LOQ of metoprolol. The expected concentrations in samples are above the obtained LOQ values for all substances.
The recoveries of probe drugs from drug-free in rat plasma were 93.8-101.0% and RSDs (relative standard deviation) were 2.24-6.42% (Table 2 ). Precision and accuracy were evaluated by replicate analysis (nϭ5) of pooled plasma at 1, 10, 50 mg/ml concentrations and in three days. As reported in Table 3 , the intraday RSDs ranged from 1.38 to 11.10%, while interday RSDs were between 3.39 and 11. 33%. The intraday accuracy ranged from 94.92 to 113.06%, while in-terday accuracy were between 92.18 and 112.62%, which is in accordance with regulatory requirements (Table 3) .
The method yielded a mean recovery of better than 90% for all the analytes, with good sensitivity, precision and accuracy for the five different probe drug. With respect to cocktail, a simple, rapid, selective analytical method is set up for simultaneous separation of the drugs in a single run.
Application In order to demonstrate the reliability of the method to evaluate the five CYP activities, all probe drugs in plasma samples were determined in rats after caudal vein injection. The dosage of the cocktail was 2.5 mg caffeine, 5 mg chlorzoxazone, 2.5 mg tolbutamide, 10 mg metoprolol and 5 mg midazolam per kg. It was used to determine all probe drugs in plasma samples 22 h after the administration of the cocktail to 6 rats. Venous blood samples were collected and plasma were separated by centrifugation at 3000 rpm for 10 min and stored frozen at 20°C until analysis. The plasma concentration-time of five probe drugs after single intravenous in rats were shown in Fig. 2 . No interference was observed with endogenous compounds and all probes. Hence, the developed analytical method is suitable for application to the evaluation of CYP1A2, 2C9, 2D6, 2E1 and 3A4 isozyme activity, respectively.
Limitation Although the cocktail approach to characterise the activity of multiple CYP isozymes offers several advantages, the analytical method remains two problems. Firstly, the LOQ of metoprolol and midazolam is not satisfied for determining lower plasma concentration in last sampling time point. Secondly, 5 probe drugs were determined in same 230 nm of UV detection, not in the best wave lenghth for The concentration of the 5 compounds is 20 mg/ml, and the internal standard is 50 mg/ml; (C) drug and internal standard extracted from a rat plasma after injection of the cocktail. Peaks: 1ϭcaffeine, 2ϭchlorzoxazone, 3ϭtolbutamide, 4ϭmetoprolol, 5ϭmidazolam, 6ϭdi-azepam (internal standard). each probe drug, so that the sensitivity was influenced. These limitations will be improved and optimized in the next research work.
CONCLUSION
A simplified, rapid, selective analytical method was set up to determine a novel 5 probe-drug cocktail (caffeine, chlorzoxazone, tolbutamide, metoprolol and midazolam) in one single run with UV detector for the evaluation of CYP1A2, 2C9, 2D6, 2E1 and 3A4 isozyme activity. In this study we used a simple liquid-liquid extraction procedure for 5 analytes (and IS) from plasma. In addition, all analytes were separated simultaneously in a single run. This novel method showed excellent specificity, linearity, sensitivity, accuracy and precision over a broad range of concentrations examined. Finally, the method was valid to determine the concentrations of the 5 probe-drug cocktail in rat plasma samples, and to evaluate the CYP isozyme activities related with this cocktail. Vol. 32, No. 4 
